| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
(Hypertension. 2004;43:885.)
© 2004 American Heart Association, Inc.
Scientific Contributions |
the Culprit?
From the Department of Pharmacology and Toxicology (C.A.N., S.W.W.), Michigan State University, East Lansing; ICOS Corporation (J.S.H.), Bothell, Wash.
Correspondence to Carrie A. Northcott, Department of Pharmacology and Toxicology, Michigan State University, B445 Life Science Bldg., East Lansing, MI 48823. E-mail taetscar{at}msu.edu
Increased expression of phosphoinositide 3-kinase (PI3-kinase) mediates elevated tone in the aorta from hypertensive deoxycorticosterone acetate (DOCA)-salt rats. In this article, we hypothesized that (1) alterations observed with respect to PI3-kinase observed in the aorta would also occur in mesenteric resistance arteries responsible for determining total peripheral resistance (TPR) and (2) p110
activity was increased and localized to vascular smooth muscle cells (VSMCs), and was responsible for the increase in spontaneous tone in aortae from DOCA-salt rats. Mesenteric resistance arteries and aorta were isolated from DOCA-salt (190±3 mm Hg) and sham (121±2 mm Hg) rats. Myograph experiments revealed LY294002 (20 µmol/L), a PI3-kinase inhibitor, significantly decreased tone in mesenteric resistance arteries from DOCA-salt rats as compared with sham (-49±12 mg versus -10±7 mg). Western analyses of resistance artery protein homogenate revealed p85
and p110
subunit protein, with significantly elevated levels of p110
protein in the DOCA-salt compared with sham rats (0.30±0.07 versus 0.16±0.04% smooth muscle alpha-actin arbitrary units). Immunohistochemistry revealed p110
-specific staining in VSMCs, with more intense staining in aortae from DOCA-salt rats. Compared with aortae from sham, p110
-associated PI3-kinase activity was increased in DOCA-salt (158% of sham) and likely responsible for spontaneous tone because the p110
specific inhibitor IC87114 decreased spontaneous tone in a concentration-dependent manner. Collectively, these data further implicate the p110
isoform of PI3-kinase in arterial hyperresponsiveness in hypertension at the level of both large and small arteries.
Key Words: arteries hypertension, mineralocorticoid
This article has been cited by other articles:
![]() |
K. Ali, M. Camps, W. P. Pearce, H. Ji, T. Ruckle, N. Kuehn, C. Pasquali, C. Chabert, C. Rommel, and B. Vanhaesebroeck Isoform-Specific Functions of Phosphoinositide 3-Kinases: p110{delta} but Not p110{gamma} Promotes Optimal Allergic Responses In Vivo J. Immunol., February 15, 2008; 180(4): 2538 - 2544. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Ding, A. Chapman, R. Boyd, and H. D. Wang ERK activation contributes to regulation of spontaneous contractile tone via superoxide anion in isolated rat aorta of angiotensin II-induced hypertension Am J Physiol Heart Circ Physiol, June 1, 2007; 292(6): H2997 - H3005. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Chansel, M. Ciroldi, S. Vandermeersch, L. F Jackson, A.-M. Gomez, D. Henrion, D. C. Lee, T. M. Coffman, S. Richard, J.-C. Dussaule, et al. Heparin binding EGF is necessary for vasospastic response to endothelin FASEB J, September 1, 2006; 20(11): 1936 - 1938. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kobayashi, Y. Hayashi, K. Taguchi, T. Matsumoto, and K. Kamata ANG II enhances contractile responses via PI3-kinase p110{delta} pathway in aortas from diabetic rats with systemic hyperinsulinemia Am J Physiol Heart Circ Physiol, August 1, 2006; 291(2): H846 - H853. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Jin, Z. Ying, R. H. P. Hilgers, J. Yin, X. Zhao, J. D. Imig, and R. C. Webb Increased RhoA/Rho-Kinase Signaling Mediates Spontaneous Tone in Aorta from Angiotensin II-Induced Hypertensive Rats J. Pharmacol. Exp. Ther., July 1, 2006; 318(1): 288 - 295. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Budzyn, P. D. Marley, and C. G. Sobey Opposing Roles of Endothelial and Smooth Muscle Phosphatidylinositol 3-Kinase in Vasoconstriction: Effects of Rho-Kinase and Hypertension J. Pharmacol. Exp. Ther., June 1, 2005; 313(3): 1248 - 1253. [Abstract] [Full Text] [PDF] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2004 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |